ScholarIQanswers from OpenAlex & ORCID
Loretta M. Itri
ResearcherPublications, citations & collaboration network
Loretta M. Itri is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Loretta M. Itri have?
ScholarIQindexed works
Loretta M. Itri has 108 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Loretta M. Itri have?
ScholarIQcitation count
Loretta M. Itri has 17,145 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Loretta M. Itri?
ScholarIQh-index
Loretta M. Itri has an h-index of 45 in OpenAlex.
What is the i10-index of Loretta M. Itri?
ScholarIQi10-index
Loretta M. Itri has an i10-index of 66 in OpenAlex.
What is the OpenAlex record for Loretta M. Itri?
ScholarIQopenalex
The OpenAlex for Loretta M. Itri is on the source record.
What are the most-cited papers on Loretta M. Itri?
ScholarIQmost cited works
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz